Aktis Oncology (AKTS) Expected to Announce Quarterly Earnings on Wednesday

Aktis Oncology (NASDAQ:AKTS) is anticipated to announce its Q1 2026 resultson Wednesday, June 3rd. Analysts expect the company to announce earnings of ($0.3335) per share and revenue of $1.75 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The business had revenue of $1.87 million for the quarter. On average, analysts expect Aktis Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aktis Oncology Stock Up 1.2%

NASDAQ AKTS opened at $20.58 on Wednesday. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16. The stock has a 50-day moving average price of $18.74.

Analyst Ratings Changes

Several research analysts have commented on AKTS shares. Leerink Partners assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price for the company. Weiss Ratings assumed coverage on shares of Aktis Oncology in a research note on Tuesday, May 12th. They issued a “sell (d)” rating for the company. TD Cowen assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target for the company. Finally, HC Wainwright upped their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aktis Oncology presently has an average rating of “Moderate Buy” and an average price target of $32.00.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.